{
    "relation": [
        [
            "Routes",
            "Oral",
            "",
            "",
            "",
            ""
        ],
        [
            "Dosage Forms",
            "Tablets, film-coated",
            "",
            "",
            "",
            ""
        ],
        [
            "Strengths",
            "5 mg",
            "30 mg",
            "35 mg",
            "75 mg",
            "150 mg"
        ],
        [
            "Brand Names",
            "Actonel",
            "Actonel",
            "Actonel",
            "Actonel",
            "Actonel"
        ],
        [
            "Manufacturer",
            "Warner Chilcott",
            "Warner Chilcott",
            "Warner Chilcott",
            "Warner Chilcott",
            "Warner Chilcott"
        ]
    ],
    "pageTitle": "Actonel Monograph for Professionals - Drugs.com",
    "title": "Risedronate Sodium",
    "url": "http://www.drugs.com/monograph/actonel.html",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 1,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987127.36/warc/CC-MAIN-20150728002307-00041-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 409082527,
    "recordOffset": 409050937,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{20453=44. Food and Drug Administration. FDA MedWatch label change: Atypical fracture update for bisphosphonates (osteoporosis drugs) including alendronate (marketed as Fosamax), alendronate with cholecalciferol (marketed as Fosamax plus D), risedronate (marketed as Actonel and Atelvia), risedronate with calcium carbonate (marketed as Actonel with Calcium), ibandronate (marketed as Boniva), and zoledronic acid (marketed as Reclast). Silver Spring, MD; 2010 Oct 13. Available from FDA website. Accessed 2010 Nov 4., 17693=34. Warner Chilcott. Actonel with Calcium (risedronate sodium with calcium carbonate) tablets MedGuide. Cincinnati, OH; 2011 Jan., 17482=33. Warner Chilcott. Actonel with Calcium (risedronate sodium with calcium carbonate) tablets prescribing information. Cincinnati, OH; 2011 Jan., 14523=21. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001; 44:1496-503. [IDIS 466759] [PubMed 11465699], 15541=25. Roux C, Oriente P, Laan R et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab. 1998; 83:1128-33. [IDIS 404610] [PubMed 9543129], 24851=61. Delmas PD, Benhamou CL, Man Z et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int. 2008; 19:1039-45. [PubMed 18087660], 18450=37. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809-22. [PubMed 17476007], 21819=48. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med. 2010; 362:1848-9. [PubMed 20463351], 22016=49. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010; 304:1480-4. [PubMed 20924014], 22222=50. Schmidt GA, Horner KE, McDanel DL et al. Risks and benefits of long-term bisphosphonate therapy. Am J Health Syst Pharm. 2010; 67:994-1001. [PubMed 20516469], 23255=54. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360:1789; author reply 1791-2., 19610=41. Food and Drug Administration. Actonel (risedronate sodium) tablets [2010 Oct 13: Warner Chilcott]. Safety labeling change and REMS notification. Silver Spring, MD; 2010 Oct 13. Available from FDA website., 15051=23. Plotkin LI, Weinstein RS, Parfitt AM et al. Prevention of osteocyte and osteoblast apoptosis by biphosphonates and calcitonin. J Clin Invest. 1999; 104:1363-74. [PubMed 10562298], 47051=Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex\u00ae (updated July 13th, 2015), Cerner Multum\u2122 (updated July 2nd, 2015), Wolters Kluwer\u2122 (updated July 2nd, 2015) and others. To view content sources and attributions, please refer to our editorial policy., 24074=57. Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010; 62:1515-26. [PubMed 20662044], 14849=22. Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res. 2000; 15:1645-9. [PubMed 10976984], 10082=1. Warner Chilcott. Actonel (risedronate sodium) tablets prescribing information. Rockaway, NJ; 2011 Feb., 9067=This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays., 21019=45. Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25:2267-94. [PubMed 20842676], 10525=4. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996; 39:1791-801. [IDIS 375200] [PubMed 8912500], 16423=28. Novartis. Zometa (zoledronic acid) injection prescribing information. East Hanover, NJ; 2008 Mar., 19874=42. Food and Drug Administration. Actonel with Calcium (risedronate and calcium carbonate) tablets [2010 Oct 13: Warner Chilcott]. Safety labeling change and REMS notification. Silver Spring, MD; 2010 (2010 Oct 13). Available from FDA website., 12096=9. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced osteoporosis treatment study. J Bone Miner Res. 2000; 15:1006-13. [PubMed 10841169], 18679=38. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007; 356:1895-6. [PubMed 17476024], 11136=6. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999; 282:1344-52. [IDIS 433492] [PubMed 10527181], 21311=46. Food and Drug Administration. FDA News Release: Possible increased risk of thigh bone fracture with bisphosphonates. Silver Spring, MD; 2010 Oct 13. Available from FDA website. Accessed 2010 Nov 4., 17889=35. Center for Drug Evaluation and Research, Food and Drug Administration. FDA Alert: Information on bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa. 2008 Jan 7. Available from FDA website. Accessed 2008 Oct 28., 10816=5. Fogelman I, Ribot C, Smith R et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000; 85:1895-900. [IDIS 446998] [PubMed 10843171], 23832=56. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360:1789-90; author reply 1791-2. [PubMed 19391255], 48328=Copyright \u00a9 2000-2015 Drugs.com. All rights reserved., 11785=8. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum. 1999; 42:2309-18. [IDIS 438381] [PubMed 10555025], 20173=43. Food and Drug Administration. FDA drug safety communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Silver Spring, MD; 2010 Oct 13. Available from FDA website. Accessed 2010 Nov 4., 18868=39. Center for Drug Evaluation and Research, Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. Bisphosphonates: alendronate (Fosamax, Fosamax plus D) etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). 2008 Nov 12. Available from FDA website. Accessed 2008 Nov 21., 23473=55. Abrahamsen B, et al. The risk of oesophageal and cancer incidence and mortality in alendronate users: a national cohort study. Presented at the 3rd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society. Athens, Greece: May 10, 2011. Abstract No. 0C29., 16867=30. Hohneker JA. Dear doctor letter regarding osteonecrosis of the jaw in patients with cancer receiving bisphophonates. East Hanover, NJ: Novartis; 2004 September 24., 9749=AHFS DI Essentials. \u00a9 Copyright, 2004-2014, Selected Revisions March 21, 2012. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814., 13706=17. National Osteoporosis Foundation. Physician\u2019s guide to prevention and treatment of osteoporosis. Washington, DC; 2000. From National Osteoporosis Foundation web site ()., 22446=51. Food and Drug Administration. FDA drug safety communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer. Rockville, MD; 2011 July 21. Available from FDA website. Accessed 2011 Sept 12.}",
    "textBeforeTable": "Specific Drugs Pharmacokinetic interaction unlikely.1 Drugs Affecting Hepatic Microsomal Enzymes Potential decreased risedronate absorption when administered with divalent cations (e.g., aluminum, calcium, magnesium).1 Antacids or Mineral Supplements Containing Divalent Cations Does not induce or inhibit CYP isoenzymes and is not metabolized.1 Interactions for Actonel Paget\u2019s disease: Arthralgia,1 diarrhea,1 headache,1 abdominal pain,1 rash,1 flu syndrome,1 nausea,1 peripheral edema,1 chest pain,1 constipation,1 dizziness.1 Postmenopausal osteoporosis: Infection (unspecified),1 33 back pain,1 8 10 arthralgia,1 8 10 33 accidental injury,1 pain (unspecified), 1 33 constipation,1 33 abdominal pain,1 5 6 8 10 urinary tract infection,1 33 nausea,1 33 diarrhea,1 33 dyspepsia,1 33 flu syndrome,1 hypertension,1 bronchitis,1 33 headache,1 arthritis,1 33 traumatic bone fracture,1 33 sinusitis,1 33 rash,1 33 dizziness,1 joint disorder,1 depression,1 33 myalgia,1 33 cataract,1 rhinitis,1 pharyngitis,1",
    "textAfterTable": "Eliminated mainly in urine; only unabsorbed drug is excreted in feces.1 Half-life Initial half-life is about 1.5 hours and terminal exponential half-life is 480 hours.1 The terminal half-life is thought to represent the dissociation of the drug from the surface of bone.1 Special Populations Renal clearance is decreased by 70% in patients with severe renal impairment (i.e., Clcr <30 mL/minute).1 Stability Storage Oral Tablets 20\u201325 \u00b0C.1 Actions and Spectrum Inhibits osteoclast-mediated bone resorption.1 2 4 5 6 8 9 12 13 14 Maintains or increases bone mineral density.1 5 6 7 8 10 18 19 20 Advice to Patients Importance of providing a copy of the manufacturer\u2019s patient information.1 Importance of proper administration (e.g., avoiding foods and beverages other than plain water, not lying down for 30 minutes following administration).1 Importance of swallowing tablets whole, without crushing, chewing, or sucking.1 Importance of discontinuing and informing clinician if symptoms of esophageal disease (e.g., difficulty or pain on swallowing; retrosternal, abdominal, or esophageal pain; severe or persistent heartburn) develop.1 Importance of adhering to recommended life-style modifications (e.g., weight-bearing exercise, calcium",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}